Rezpeg's Phase 3 Leap: Nektar's Treg Agonist Moves to Registration with Strong Cash and a Differentiated MOA
NKTR initiates global Phase 3 in atopic dermatitis, secures FDA alignment for alopecia areata, and extends cash runway into 2028.
NKTR · Earnings Call · 2026-08-13
The Transition to Registration
Nektar Therapeutics (NKTR, ~$2.3B market cap) delivered a milestone-heavy Q2 2026 call. The company initiated ZENITH AD, its global Phase 3 program for rezpeg (aldesleukin) in moderate-to-severe atopic dermatitis, and reached alignment with the FDA on a single registrational Phase 3 study (ZENITH AA) in alopecia areata. These are not incremental steps; they mark the transition from proof-of-concept to registration for a novel mechanism of action that management believes can fundamentally change treatment paradigms.
Howard Robin framed the significance: “With the first phase 3 studies in atopic dermatitis now underway, we expect top line data from these studies in mid-2028” and a potential BLA in 2029. The cash position supports this runway—cash runway extends into Q3 2028, past the initial readouts. Linda Rubinstein confirmed: “We ended the second quarter with $1.02 billion in cash and investments with no debt on our balance sheet.” — Linda Rubinstein, Chief Financial Officer · 2026-08-13 That is a war chest for a company that just a few quarters ago was exploring partnerships to fund Phase 3.
Physician Enthusiasm and a Differentiated MOA
The call leaned heavily on market research to validate positioning. Howard detailed interviews with 151 high-volume prescribers, emphasizing that physicians welcome a novel mechanism distinct from the IL-13 class. He noted: “We recently completed extensive market research which included our 52-week maintenance data for rezpeg. The research reinforces our commercial thesis in atopic dermatitis.” — Howard W. Robin, President and Chief Executive Officer · 2026-08-13
The safety profile is a key differentiator. As Howard stated in a block quote:
We know that roughly half of the patients on currently available IL-13-based agents, including Dupixent, either do not respond to therapy or lose their response over time. This leaves a large unmet need for a new therapeutic option.
Moreover, 150 of 151 physicians said injection-site reactions (ISRs) were not a barrier, preferring a self-resolving ISR over managing conjunctivitis. This directly counters a potential commercial hurdle.
Data, Durability, and Expanding Comorbidities
Maintenance data from the Phase 2b RESOLVE AD study showed deepening responses—up to 5-fold increases in EASI-100 rates during maintenance. The company is building on this with new endpoints that address comorbidities. Jonathan Zalevsky highlighted SNOT 22, a sinonasal outcome measure, as a secondary endpoint: “We are including SNOT 22 as a secondary endpoint in our phase 3 study and we are excited to share with you that we plan to present this non 22 data from the RESOLVE AD study at a future medical meeting.” — Jonathan Zalevsky, Chief Research and Development Officer · 2026-08-13 This is a fresh pivot—the company is now targeting allergic rhinitis and asthma as part of the product's value proposition, not just skin clearance.
The off-treatment data from alopecia areata (Q4 2026) and atopic dermatitis (Q1 2027) will inform maintenance dosing. Mary Tagliaferri, in a prior call, set the expectation: “I think this will be highly informative again to understand the dosing frequency for these patients after they're treated with 52 weeks of treatment.” — Mary Tagliaferri, Unknown · 2026-05-08 The company aims to extend dosing intervals beyond quarterly, potentially offering a remittive effect no JAK inhibitor can match.
Financial Position and Execution
R&D expense is stepping up as Phase 3 begins. The company guided full-year 2026 R&D to $210–230M, a sharp increase from the Q2 run rate. Historical data show R&D peaked at $109M in 2019, bottomed near $24M in 2023, and is now inflecting upward. The 10-year trajectory reflects the platform pivot from oncology to immunology, with spending now concentrated on rezpeg's late-stage development. With no debt and a $1.02B cash balance, NKTR is self-funding through key catalysts.
However, execution risk remains. The company faces an ongoing patent litigation with Lilly—trial scheduled September 8. Howard declined to comment beyond reiterating a strong position. Additionally, the competitive landscape in AD is crowded, with STAT6 inhibitors and other mechanisms. Yet, as JZ argued, rezpeg's upstream Treg agonism is mechanistically distinct, a point that resonates with the mechanism of action enthusiasm.
Recurring Themes and Risks
The Phase 3 design with separate studies for naive and experienced patients was previewed in Q1 2026. Mary Tagliaferri then explained: “We do feel it is important to be able to compare the results of the REZPEG study on the EASI-75, the IGA and other secondary endpoints directly to those cytokine blocking agents.” — Mary Tagliaferri, Unknown · 2026-05-08 This consistency underscores a disciplined regulatory path.
What has changed now is the breadth of ambition. The company is no longer just a dermatitis play; it is building a Treg platform across autoimmune diseases, including type 1 diabetes and TNF-R2 bispecifics. The new indications and endpoints (SNOT 22, ACQ-5) are evidence of that expansion. The market research provides a commercial rationale, but the ultimate test will be Phase 3 data in 2028. For now, NKTR's stock remains well below its 2018 peak, but the de-risking of program design and the strong balance sheet make it a name to watch.